Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Vokes NI, Chambers E, Nguyen T, Coolidge A, et al. J Thorac Oncol 2022;17:779-792.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Vokes NI, Chambers E, Nguyen T, Coolidge A, et al. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol 2022;17:779-792.
PMID: 35331964